Literature DB >> 3356850

Release of leukotrienes in patients with bronchial asthma.

S Lam1, H Chan, J C LeRiche, M Chan-Yeung, H Salari.   

Abstract

To investigate whether leukotrienes (LTs) are released into the bronchial fluid of patients with symptomatic asthma, bronchial lavage was carried out in 17 patients with mild to severe asthma and nine healthy subjects without asthma. LTE4 was detected in 15 of the 17 patients with asthma with reverse-phase high-performance liquid chromatography. The identify of LTE4 was confirmed by ultraviolet spectrometry and by positive ion fast atom-bombardment mass spectrometry. LTD4 was found in two patients and 20-OH-LTB4 in 12 patients. No LTs were detectable in the lavage fluid from any of the healthy subjects without asthma. The finding of LTs in bronchial lavage fluid from the patients with asthma despite bronchodilator and/or corticosteroid therapy suggests that these compounds may be important in asthma. However, the presence of significant quantities of LTE4 in patients with mild asthma requiring only intermittent bronchodilator therapy for control and the lack of correlation between LTE4 and pulmonary function also suggests that other factors may be important in determining the net end organ response. The present study points to the importance of studying the whole spectrum of mediators that are released. Analysis of bronchial lavage fluid may be useful in determining the relative role of these mediators and the effect of pharmacologic intervention.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356850     DOI: 10.1016/0091-6749(88)91043-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Regulation of expression of the 5-lipoxygenase pathway.

Authors:  T D Bigby
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Lipoxins and other arachidonate derived mediators in bronchial asthma.

Authors:  C Chavis; I Vachier; P Godard; J Bousquet; P Chanez
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 4.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

5.  Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects.

Authors:  A P Sampson; R U Thomas; J F Costello; P J Piper
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

6.  Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats.

Authors:  M Salmon; D A Walsh; T J Huang; P J Barnes; T B Leonard; D W Hay; K F Chung
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

7.  Leukotriene B4 and asthma.

Authors:  P E Christie; N C Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

8.  Ultrastructural analysis of leukocytes recruited into the guinea pig lung by LTB4 aerosol.

Authors:  A Shay; T Connolly; D N Smith; G L Crean
Journal:  Agents Actions       Date:  1989-06

9.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

10.  Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor.

Authors:  Sailaja Paruchuri; Hiroyuki Tashimo; Chunli Feng; Akiko Maekawa; Wei Xing; Yongfeng Jiang; Yoshihide Kanaoka; Pamela Conley; Joshua A Boyce
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.